



Current Agreements

Dealdoc

Co-development agreement for the MET/VEGFR-2 inhibitor BMS-817378 for cancer (expanded)

Simcere Pharmaceuticals
Bristol-Myers Squibb

Nov 03 2010

Co-development agreement for the MET/VEGFR-2 inhibitor BMS-817378 for cancer (expanded)

Companies:	Simcere Pharmaceuticals Bristol-Myers Squibb
Announcement date:	Nov 03 2010
Amendment date:	Jun 14 2013
Related contracts:	Co-development agreement for BMS-795311

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Nov 03 2010
Amendment date:	Jun 14 2013
Industry sectors:	Pharmaceutical
Brand name:	Orencia
Therapy areas:	Musculoskeletal » Arthritis » Rheumatoid arthritis Oncology
Technology types:	Small molecules
Deal components:	Co-development
Stages of development:	Preclinical
Geographic focus:	Asia » China
Excluded geography:	Worldwide

Financials

Termsheet

14 June 2013

Bristol-Myers Squibb Company and Simcere Pharmaceutical Group have expanded their strategic relationship formed in 2010.

The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous formulation of Bristol-Myers Squibb's biologic medicine, Orencia (abatacept), for the treatment of rheumatoid arthritis.

Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.

3 November 2010

BMS and Simcere Pharmaceutical announced a strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.

Simcere receives exclusive rights to develop and commercialize BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets.

The parties will together determine the strategic development plan, which will initially be performed by Simcere.

Financial terms were not disclosed.

Press Release

14 June 2013

Bristol-Myers Squibb Company (BMY), Sincere Pharmaceutical Group Form Pact for Development of RA Treatment

6/14/2013 7:14:42 AM

Bristol-Myers Squibb and Sincere Enter Partnership to Co-Develop and Co-Commercialize Orenia® SC (abatacept) in China

PRINCETON, N.J. & NANJING, China-- Bristol-Myers Squibb Company (BMY) and Sincere Pharmaceutical Group (SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orenia® (abatacept), for the treatment of rheumatoid arthritis. Orenia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.

Under the terms of the agreement, Sincere will perform and fund all development and regulatory activities required to obtain market approval for Orenia SC in China, based on a pre-agreed development plan. The companies will share responsibility for commercializing Orenia, and will share profits and losses related to Orenia SC in China. Financial terms were not disclosed.

"Orenia SC is the third program in our R&D collaboration with Bristol-Myers Squibb, underscoring our joint commitment to our broad strategic partnership," commented Mr. Hongquan Liu, the CEO of Sincere. "Combining Orenia SC with our existing portfolio in rheumatoid arthritis treatment, we are committed to delivering more innovative and effective medicines to Chinese patients."

Mr. Hongquan Liu further commented, "Moving forward, we will continue to execute on our partnering strategy and to bring in more late-stage programs and products already approved outside of China, to complement our R&D pipeline and strengthen our in-market portfolio."

"We are pleased to partner with Sincere on Orenia SC, moving beyond our companies' original focus on early development activities to a partnership focused on the clinical development and commercialization of one of our currently marketed products," said Beatrice Cazala, executive vice president, Commercial Operations. "If successful, not only could Orenia SC bring a new option to Chinese patients suffering from rheumatoid arthritis, but also it could become Bristol-Myers Squibb's first biologic medicine for the Chinese market."

About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at <http://twitter.com/bmsnews>.

About Sincere Pharmaceutical Group Sincere Pharmaceutical Group (NYSE:SCR, Sincere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. Sincere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective therapy, including cancer, strokes, cardiovascular diseases, infectious diseases and pain. For more information about Sincere Pharmaceutical Group, please visit <http://www.sincere.com>.

Bristol-Myers Squibb Forward Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that Orenia SC will become a commercially successful product in China. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Sincere Safe Harbor Statement This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Sincere's filing with the U.S. Securities and Exchange Commission at <http://www.sec.gov>. Sincere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

3 November 2010

Simcere Pharmaceutical Group and Bristol-Myers Squibb Company (BMY) Enter Innovative Partnership to Develop Early-Stage Oncology Compound

China and PRINCETON, N.J., Nov. 3, 2010 /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor. This unique arrangement represents a creative approach to accelerate a preclinical oncology compound to clinical proof-of-concept by leveraging the complementary strengths of a premier Chinese pharmaceutical company and a global pharmaceutical company. This partnership represents a novel development stage relationship for Bristol-Myers Squibb with a Chinese company, and a novel partnership approach for Bristol-Myers Squibb to leverage its early stage pipeline in support of its BioPharma strategy.

Under the terms of the agreement, Simcere receives exclusive rights to develop and commercialize BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets. The parties will together determine the strategic development plan, which will initially be performed by Simcere. Financial terms were not disclosed.

"This ground-breaking partnership demonstrates how a leading research and development based Chinese company can work together with a global pharmaceutical company to accelerate a drug development timeline and conduct first-in-human studies in China. This approach allows the partnership to leverage our well-recognized clinical and regulatory capabilities and our access to the vast patient pool in China," commented Dr. Peng Wang, chief scientific officer, Simcere Pharmaceutical Group.

"We are committed to working with companies in China in a creative and innovative fashion. This new partnership represents just such an example," said Francis Cuss, senior vice president, Research, Bristol-Myers Squibb. "We are excited to embark on this partnership with Simcere. Working together we are building on the strengths of both organizations to develop potential medicines and help patients."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at <http://twitter.com/bmsnews>.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit <http://www.simcere.com>.

Bristol-Myers Squibb Forward Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the compound described in this release will move from exploratory development into full product development, that clinical trials of this compound will support a regulatory filing, or that the compound will receive regulatory approval or become a commercially successful product. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2009, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Filing Data

Not available.

Contract

Not available.